Skip to main content
ResearchTreatments

Osimertinib Combos Under Evaluation to Improve Outcomes, Combat Resistance in EGFR+ NSCLC

By June 20, 2021November 7th, 2021No Comments

*April 2021*

Jyoti D. Patel, MD, discusses how the FDA approval of adjuvant osimertinib has impacted the treatment of patients with EGFR-positive NSCLC, efforts being made to overcome resistance to the third-generation EGFR TKI, and other approaches under exploration that may serve to further improve outcomes in this population.

Read more.